



(11) **EP 2 925 338 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 9/00 ^(2006.01) **A61K 9/19** ^(2006.01)
A61K 38/08 ^(2019.01) **A61K 38/10** ^(2006.01)
A61K 38/17 ^(2006.01) **A61K 47/18** ^(2017.01)
A61K 47/26 ^(2006.01)

(48) Corrigendum issued on:
22.05.2019 Bulletin 2019/21

(86) International application number:
PCT/US2013/071755

(45) Date of publication and mention
of the grant of the patent:
27.03.2019 Bulletin 2019/13

(87) International publication number:
WO 2014/085349 (05.06.2014 Gazette 2014/23)

(21) Application number: **13859059.1**

(22) Date of filing: **25.11.2013**

(54) **LYOPHILIZED FORMULATION OF TAT-NR2B9C**
LYOPHILISIERTE FORMULIERUNG VON TAT-NR2B9C
FORMULATION LYOPHILISÉE DE TAT-NR2B9C

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **28.11.2012 US 201261730952 P**

(43) Date of publication of application:
07.10.2015 Bulletin 2015/41

(73) Proprietor: **NoNO Inc.**
Toronto, ON M8X 1R5 (CA)

(72) Inventor: **GARMAN, Jonathan David**
Thornhill, Ontario L4J 8N1 (CA)

(74) Representative: **Nederlandsch Octrooibureau**
P.O. Box 29720
2502 LS The Hague (NL)

(56) References cited:
WO-A2-2012/021854 US-A- 5 605 884
US-A1- 2007 140 981 US-A1- 2010 082 985
US-A1- 2012 252 731 US-B2- 7 060 268

- **CARPENTER J F ET AL: "RATIONAL DESIGN OF STABLE LYOPHILIZED PROTEIN FORMULATIONS: THEORY AND PRACTICE", PHARMACEUTICAL BIOTECHNOLOGY, KLUWER, DORDRECHT, NL, vol. 13, 1 January 2002 (2002-01-01), pages 109-133, XP009053337, ISSN: 1078-0467**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).
